Ruxopeg, a Multi-Center Bayesian Phase 1/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated MyelofibrosisJean‐Jacques Kiladjian, Bruno Cassinat, Claude Capron et al.|Blood|2018Cited by 26
Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)Jean‐Jacques Kiladjian, Bruno Cassinat, Jean‐Christophe Ianotto et al.|Blood|2022Cited by 21
Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study CovimLaurence Legros, Jean‐Jacques Kiladjian, Françoise Boyer perrard et al.|Blood|2022Cited by 0